Elevated Fas/FasL system and endothelial cell microparticles are involved in endothelial damage in acute graft-versus-host disease: A clinical analysis

Leukemia Research

Volumn 36, Issue 3, 2012, Pages 275-280

  Wu, Qiuling ^a   Chen, Huixin ^a,b   Fang, Jun ^a   Xie, Wei ^a   Hong, Mei ^a   Xia, Linghui ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN NO 1 HOSPITAL   (China)

Author keywords

Acute graft versus host disease; Allogeneic hematopoietic stem cell transplantation; Endothelial cell microparticles; Fas antigen; Soluble Fas ligand

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; FAS ANTIGEN; FAS LIGAND; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CELL SURFACE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; ENDOTHELIAL MICROPARTICLE; ENDOTHELIUM INJURY; FEMALE; HUMAN; HUMAN CELL; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; ANTIGENS, CD95; CASE-CONTROL STUDIES; CELL-DERIVED MICROPARTICLES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; FEMALE; FLOW CYTOMETRY; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, NON-HODGKIN; MALE; MYELODYSPLASTIC SYNDROMES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84855940726     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.08.005     Document Type: Article

References (29)

1. Socie G., Salooja N., Cohen A., Rovelli A., Carreras E., Locasciulli A., et al. Nonmalignant late effects after allogeneic stem cell transplantation. Blood 2003, 101(9):3373-3385. [Pub Med: 12511420].
2. Ferrara J.L., Reddy P. Pathophysiology of graft-versus-host disease. Semin Hematol 2006, 43(1):3-10. [Pub Med: 16412784].
3. Biedermann B.C. Vascular endothelium and graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21(2):129-138. [Pub Med: 18503981].
4. Tichelli A., Gratwohl A. Vascular endothelium as " novel" target of graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21(2):139-148. [Pub Med: 18503982].
5. Deschaumes C., Verneuil L., Ertault-Daneshpouy M., Adle-Biassette H., Galateau F., Ainoun F., et al. CD95 ligand-dependant endothelial cell death initiates oral mucosa damage in a murine model of acute graft versus host disease. Lab Invest 2007, 87(5):417-429.
6. Nagata S. Apoptosis by death factor. Cell 1997, 88(3):355-365. [Pub Med: 9039262].
7. Kondo T., Suda T., Fukuyama H., Adachi M., Nagata S. Essential roles of the Fas ligand in the development of hepatitis. Nat Med 1997, 3:409-413. [Pub Med: 9095174].
8. Schmaltz C., Alpdogan O., Horndasch K.J., Muriglan S.J., Kappel B.J., Teshima T., et al. Differential use of Fas ligand and perforin cytotoxic pathway by donor T-cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 2001, 97(9):2886-2895. [Pub Med: 11313285].
9. Sun Y., Tawara I., Toubai T., Reddy P. Pathophysiology of acute graft-vs-host disease: recent advances. Transl Res 2007, 150(4):197-214. [Pub Med: 17900507].
10. Jaksch M., Uzunel M., Martinez Cangana G., Remberger M., Mattsson J. Increased levels of immune transcript in patients with acute GVHD after allogenic stem cell transplantation. Bone Marrow Transplant 2003, 31(3):183-190. [Pub Med: 12621479].
11. Georgantas R.W., Bohana-Kashtan O., Civin C.I. Ex vivo soluble fas ligand treatment of donor cells to selectively reduce murine acute graft versus host disease. Transplantation 2006, 82(4):471-478. [Pub Med: 16926590].
12. Bohana-Kashtan O., Morisot S., Hildreth R., Brayton C., Levitsky H.I., Civin C.I. Selective reduction of graft-versus-host disease-mediating human T cells by ex vivo treatment with soluble Fas ligand. J Immunol 2009, 183(1):696-705. [Pub Med: 19535642].
13. Morel O., Toti F., Hugel B., Freyssinet J.M. Cellular microparticles, a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 2004, 11(3):156-164. [Pub Med: 15257014].
14. Woywodt A., Scheer J., Hambach L., Buchholz S., Ganser A., Haller H., et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood 2004, 103(9):3603-3605. [Pub Med: 14715625].
15. Pihusch V., Rank A., Steber R., Pihusch M., Pihusch R., Toth B., et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipients. Transplantation 2006, 81(10):1405-1409. [Pub Med: 16732177].
16. Przepiorka D., Weisdorf D., Martin P., Klingemann H.G., Beatty P., Hows J., et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995, 15(6):825-828.
17. Horstman L.L., Jy W., Jimenez J.J., Bidot C., Ahn Y.S. New horizons in the analysis of circulating cell-derived microparticles. Keio J Med 2004, 53(4):210-230. [PubMed: 15647627].
18. Tesfamariam B., DeFelice A.F. Endothelial injury in the initiation and progression of vascular disorders. Vasc Pharmacol 2007, 46(4):229-237.
19. Biedermann B.C., Tsakiris D.A., Gregor M., Pober J.S., Gratwohl A. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transpl 2003, 32:1077-1084.
20. Matsuda Y., Hara J., Osugi Y., Tokimasa S., Fujisaki H., Takai K., et al. Serum levels of soluble adhesion molecules in stem cell transplantation-related complications. Bone Marrow Transpl 2001, 27(9):977-982.
21. Densmore J.C., Signorino P.R., Ou J., Hatoum O.A., Rowe J.J., Shi Y., et al. Endothelium-derived microparticles induce endothelial dysfunction and acute lung injury. Shock 2006, 26(5):464-471. [Pub Med: 17047516].
22. Mezentsev A., Merks R.M., O'Riordan E., Chen J., Mendelev N., Goligorsky M.S., et al. Endothelial microparticles affect angiogenesis in vitro: role of oxidative stress. Am J Physiol Heart Circ Physiol 2005, 289(3):H1106-H1114. [Pub Med: 15879485].
23. Brodsky S.V., Zhang F., Nasjletti A., Goligorsky M.S. Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 2004, 286(5):H1910-H1915. [Pub Med: 15072974].
24. Nomura S., Ishii K., Inami N., Kimura Y., Uoshima N., Ishida H., et al. Evaluation of angiopoietins and cell-derived microparticles after stem cell transplantation. Biol Blood Marrow Transplant 2008, 14(7):766-774. [Pub Med: 18541195].
25. Abrahams V.M., Straszewski-Chavez S.L., Guller S., Mor1 G. First trimester trophoblast cells secrete Fas ligand which induces immune cell apoptosis. Mol Hum Reprod 2004, 10(1):55-63. [Pub Med: 14665707].
26. D'Agostino S., Salamone M., Di Liegro I., Vittorelli L. Membrane vesicles shed by oligodendroglioma cells induce neuronal apoptosis. Int J Oncol 2006, 29(5):1075-1085. [Pub Med: 17016637].
27. Albanese J., Meterissian S., Kontogiannea M., Dubreuil C., Hand A., Sorba S., et al. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extra cellular vesicles. Blood 1998, 91(10):3862-3874. [Pub Med: 9573024].
28. Koide N., Morikawa A., Tumurkhuu G., Dagvadorj J., Hassan F., Islam S., et al. Lipopolysaccharide and interferon-gamma enhance Fas-mediated cell death in mouse vascular endothelial cells via augmentation of Fas expression. Clin Exp Immunol 2007, 150(3):553-560. [Pub Med: 17900305].
29. Sata M., Luo Z., Walsh K. Fas ligand overexpression on allograft endothelium inhibits inflammatory cell infiltration and transplant-associated intimal hyperplasia. J Immunol 2001, 166(11):6964-6971. [Pub Med: 11359858].